Friedberg Investment Management Has Trimmed By $452,400 Its Diplomat Pharmacy (DPLO) Stake; Barrick Gold (TSE:ABX) Had 5 Bullish Analysts

September 17, 2017 - By Peter Erickson

Friedberg Investment Management decreased Diplomat Pharmacy (DPLO) stake by 63.2% reported in 2016Q4 SEC filing. Friedberg Investment Management sold 37,700 shares as Diplomat Pharmacy (DPLO)’s stock rose 20.96%. The Friedberg Investment Management holds 21,950 shares with $276,000 value, down from 59,650 last quarter. Diplomat Pharmacy now has $1.34B valuation. The stock increased 0.97% or $0.19 on September 15, reaching $19.68. About 1.82 million shares traded or 197.45% up from the average. Diplomat Pharmacy Inc (NYSE:DPLO) has declined 40.48% since September 17, 2016 and is downtrending. It has underperformed by 57.18% the S&P500.

Among 10 analysts covering Barrick Gold Corp. (TSE:ABX), 5 have Buy rating, 0 Sell and 5 Hold. Therefore 50% are positive. Barrick Gold Corp. had 36 analyst reports since July 24, 2015 according to SRatingsIntel. BMO Capital Markets maintained the stock with “Outperform” rating in Friday, April 7 report. The company was upgraded on Friday, July 31 by Canaccord Genuity. The firm has “Outperform” rating given on Monday, April 24 by RBC Capital Markets. The stock of Barrick Gold Corp (TSE:ABX) earned “Sector Perform” rating by RBC Capital Markets on Friday, September 2. The firm has “Sector Perform” rating given on Friday, January 22 by RBC Capital Markets. TD Securities maintained it with “Hold” rating and $18 target in Thursday, January 26 report. The firm has “Sector Perform” rating by RBC Capital Markets given on Tuesday, October 25. The stock has “Sector Perform” rating by Scotia Capital on Friday, April 7. The firm has “Market Perform” rating given on Thursday, July 6 by BMO Capital Markets. The firm has “Neutral” rating by JP Morgan given on Thursday, February 4. See Barrick Gold Corp (TSE:ABX) latest ratings:

06/07/2017 Broker: BMO Capital Markets Rating: Market Perform New Target: $18.00 Maintain
30/06/2017 Broker: BMO Capital Markets Rating: Outperform New Target: $21.00 Maintain
23/06/2017 Broker: RBC Capital Markets Rating: Outperform Maintain
24/04/2017 Broker: RBC Capital Markets Rating: Outperform Maintain
07/04/2017 Broker: BMO Capital Markets Rating: Outperform New Target: $24.00 Maintain
07/04/2017 Broker: Scotia Capital Rating: Sector Perform New Target: $30.00 Maintain
07/04/2017 Broker: TD Securities Rating: Hold New Target: $27.00 Maintain
29/03/2017 Broker: Canaccord Genuity Rating: Buy Old Target: $30.00 New Target: $31.00 Target Up

The stock increased 0.86% or $0.18 on September 15, reaching $21.07. About 9.84M shares traded or 351.38% up from the average. Barrick Gold Corp (TSE:ABX) has 0.00% since September 17, 2016 and is . It has underperformed by 16.70% the S&P500.

Barrick Gold Corporation is a gold mining company. The company has market cap of $24.64 billion. The Firm is principally engaged in the production and sale of gold and copper, as well as related activities, such as exploration and mine development. It has a 8.55 P/E ratio. The Company’s divisions include Goldstrike, Cortez, Pueblo Viejo, Lagunas Norte, Veladero, Turquoise Ridge, Acacia Mining plc (Acacia), Pascua-Lama and Other Mines.

Investors sentiment increased to 2.27 in 2016 Q4. Its up 1.06, from 1.21 in 2016Q3. It is positive, as 39 investors sold DPLO shares while 48 reduced holdings. 30 funds opened positions while 52 raised stakes. 42.49 million shares or 16.74% less from 51.03 million shares in 2016Q3 were reported. Old Natl Commercial Bank In holds 0.01% or 15,154 shares. Vanguard holds 0% or 3.39M shares. Ny State Common Retirement Fund owns 47,500 shares. 64,400 were accumulated by Swiss Comml Bank. Mason Street Limited holds 9,365 shares. The New York-based Jpmorgan Chase has invested 0% in Diplomat Pharmacy Inc (NYSE:DPLO). Moreover, Gabelli Funds Ltd Liability Corporation has 0% invested in Diplomat Pharmacy Inc (NYSE:DPLO) for 49,000 shares. Cipher Limited Partnership holds 0.01% or 16,710 shares in its portfolio. Group One Trading Limited Partnership holds 0% or 2,850 shares. First Interstate Financial Bank has invested 0% in Diplomat Pharmacy Inc (NYSE:DPLO). Price T Rowe Assoc Incorporated Md owns 0.01% invested in Diplomat Pharmacy Inc (NYSE:DPLO) for 2.38M shares. Wells Fargo And Com Mn invested 0% in Diplomat Pharmacy Inc (NYSE:DPLO). The United Kingdom-based Hermes Limited has invested 0.33% in Diplomat Pharmacy Inc (NYSE:DPLO). Aberdeen Asset Mgmt Public Limited Company Uk has invested 0% of its portfolio in Diplomat Pharmacy Inc (NYSE:DPLO). Employees Retirement Systems Of Texas has 0.01% invested in Diplomat Pharmacy Inc (NYSE:DPLO) for 50,000 shares.

Among 12 analysts covering Diplomat Pharmacy (NYSE:DPLO), 4 have Buy rating, 1 Sell and 7 Hold. Therefore 33% are positive. Diplomat Pharmacy had 23 analyst reports since August 4, 2015 according to SRatingsIntel. The stock of Diplomat Pharmacy Inc (NYSE:DPLO) earned “Underperform” rating by Credit Suisse on Wednesday, November 23. Cowen & Co initiated Diplomat Pharmacy Inc (NYSE:DPLO) on Friday, June 24 with “Market Perform” rating. Bank of America maintained the stock with “Neutral” rating in Tuesday, June 7 report. The firm earned “Buy” rating on Wednesday, October 21 by Mizuho. The firm has “Neutral” rating given on Wednesday, October 14 by Bank of America. Mizuho maintained the stock with “Neutral” rating in Wednesday, May 11 report. The firm has “Buy” rating by Robert W. Baird given on Tuesday, August 8. The stock of Diplomat Pharmacy Inc (NYSE:DPLO) earned “Overweight” rating by Barclays Capital on Wednesday, January 6. The firm has “Mkt Perform” rating given on Thursday, November 3 by Leerink Swann. As per Tuesday, August 4, the company rating was maintained by Leerink Swann.

Analysts await Diplomat Pharmacy Inc (NYSE:DPLO) to report earnings on November, 1. They expect $0.15 EPS, down 28.57% or $0.06 from last year’s $0.21 per share. DPLO’s profit will be $10.21 million for 32.80 P/E if the $0.15 EPS becomes a reality. After $0.25 actual EPS reported by Diplomat Pharmacy Inc for the previous quarter, Wall Street now forecasts -40.00% negative EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Twitter Auto Publish Powered By : XYZScripts.com